A Δ‑Based Framework For Internal Release Limits In Plateau Stability Systems.

Area of Science:

• Pharmaceutical Manufacturing
• Analytical Chemistry
• Statistics

Background:

• Internal Release Limits (IRLs) are typically set using statistical methods like time-series regression for shelf-life assignment.
• These methods assume identifiable degradation slopes and require prediction beyond observed timepoints, which may not hold true for sparse or plateauing stability data.
• Regression-based inference can be statistically unsupported in practical IRL scenarios.

Purpose of the Study:

• To introduce a Δ-based framework for Internal Release Limit (IRL) determination that is model-independent and data-appropriate.
• To formalize identifiability conditions, certify plateau behavior, and partition variance in stability datasets.
• To provide explicit future-batch population coverage using one-sided tolerance intervals.

Main Methods:

• Development of a Δ-based framework for IRL determination.
• Formalization of identifiability conditions and plateau certification.
• Application of one-sided tolerance intervals for future-batch coverage.
• Validation through simulation studies and analysis of a monoclonal antibody dataset.

Main Results:

• The Δ-based framework provides direct and accurate estimates of future-batch-protective release limits, outperforming model-based approaches in plateauing systems.
• Application to a monoclonal antibody dataset demonstrates transformation of sparse stability data into a regulatorily actionable strategy.
• The framework recovers IRL decisions consistent with time-dependent modeling under weaker assumptions when plateau behavior is verified.

Conclusions:

• The Δ-based IRL determination is the identifiable limiting case for stability systems with time-invariant late-age behavior and unreliably estimable kinetic parameters.
• This approach offers greater uncertainty transparency and aligns with analytical lifecycle management expectations.
• It provides a robust and regulatorily actionable strategy for IRLs, particularly for biologics with plateauing stability profiles.